Geldanamycin

製品コードS2713 別名:NSC 122750

Geldanamycin化学構造

分子量(MW):560.64

Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

サイズ 価格(税別)  
JPY 28220.00
JPY 44820.00
JPY 111220.00

カスタマーフィードバック(3)

  • Phenotypic effect of Genetic or Pharmacologic Compromise of the 477 Hsp70-StiA-Hsp90 Complex. The impact of each genetic modification on radial growth, conidiation, and response to various stress conditions was assessed after inoculation of a suspension of 104 conidia on glucose minimal medium (GMM) agar plates and incubation at 37ºC for 5 days.

    Antimicrob Agents Chemother, 2015, 10.1128/AAC.00946-15. Geldanamycin purchased from Selleck.

    C2C12 myoblasts were transfected with HA-tagged A17-PABPN1 constructs. Twenty-four hours post-transfection, cells were treated with CHX (10 μg/ml) alone or together with geldanamycin (2.5 μM) for the indicated times at 37°C. Lysates were blotted to show the expression of the proteins of interest. Band density was quantified and is shown in the line graph (right panels). Data are shown as the mean ± SEM (n = 5); **, P < 0.01.

    PLoS One, 2015, 10(9):e0138936.. Geldanamycin purchased from Selleck.

  • RT-qPCR analysis of eNOS mRNA and representative Western blot images of eNOS expression, respectively, in irradiated BAECs pretreated of geldanamycin (GA; 500 nM). At 12 h after 10 Gy irradiation, BAECs were harvested. The results suggest that both HSP90 is involved in the upregulation of eNOS in irradiated BAECs.

    Radiat Res, 2018, 189(5):519-528. Geldanamycin purchased from Selleck.

製品安全説明書

HSP (e.g. HSP90)阻害剤の選択性比較

生物活性

製品説明 Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
ターゲット
p185 [4]
(SKBr3 cells)
HSP90 (N-terminal domain) [1]
(Cell-free assay)
HSP90 [1]
(Cell-free assay)
70 nM 0.78 μM(Kd) 1.2 μM(Kd)
体外試験

Geldanamycin binds in the ATP-binding site in the N-terminus domain of Hsp90s (residues 1-220). Geldanamycin inhibits the ATPase activity of Hsp90 in a dose-dependent manner. [1] Geldanamycin causes a dose-dependent G2 arrest and reversible inhibiton o f entry into the S phase in A2780 human ovarian cell line. This inhibition is accompanied by p53 increase and finally demonstrated to be p53 dependent. [2] Geldanamycin causes polyubiquitination and proteasomal degradation of the p185 receptor protein-tyrosin kinase and shows a IC50 with 70 nM. [3, 4] Geldanamycin is a typical anti-tumor reagent, shows a mean GI50 with 0.18 μM against the panel of 60 human tumor cell lines. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A2780 cells MXTQdo9tcW[ncnH0bY9vKGG|c3H5 NXrPN|JJS2:vcH;1coQhf2G|IHX2ZYx2[XSnZDDmc5Ih[W62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKGyrbnWgRVI4QDBuIFnDOVA:Oy52IN88US=> NWC4N|k5OTF3MUSxOFU>
SW620 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{H4XmlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKGOxbH;y[YN1[WxiY3HyZ4lvd22jIGPXOlIxKGOnbHygcIlv\XNuIFnDOVA:Pi5{IH7N MUexOVY2QDh5OR?=
MCF-7 cell MnzsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4nsbmlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKGK{ZXHzeEBk[W6lZYKgUWNHNTdiY3XscEBtcW6nczygTWM2OD14LkWgcm0> MUKxOVY2QDh5OR?=
SKBR3 cells NWPhdZBkWHKxbHnm[ZJifGmxbjDhd5NigQ>? MV23NkBp MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHXzeJJw\2WwIILlZ4VxfG:{IHTl[olkcWWwdDDoeY1idiCVS1LSN{Bk\WyuczDh[pRmeiB5MjDodpMtKEmFNUC9PE42KG6P NHPuWZczOzZ2OEG4NC=>
MCF7 cells NGfxOHdRem:uaX\ldoF1cW:wIHHzd4F6 M4jOclczKGh? NVTaWo1VSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4Ppcoch\XO2cn;n[Y4hemWlZYD0c5Ih[W[2ZYKgO|IhcHK|LDDJR|UxRTlwODDuUS=> NYTLboJ3OjN4NEixPFA>
MDA-kb2 cells NF\ldVhHfW6ldHnvckBie3OjeR?= NYe0eJZHOThiaB?= M1rRNGlvcGmkaYTpc44hd2ZiSGPQPVAhcW5iaIXtZY4hVUSDLXviNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iZ3z1Z49kd3K2aXPvbYQhemWlZYD0c5Iu\GWyZX7k[Y51KGy3Y3nm[ZJie2ViZYjwdoV{e2mxbjDh[pRmeiBzODDodpMh[nliZnny[YZtgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTB;MUCgcm0> MmfFNlQ6QDR7M{[=
human SK-BR-3 cells NGH6PYZRem:uaX\ldoF1cW:wIHHzd4F6 NH;3[5RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMWJTNTNiY3XscJMtKEmFNUC9NVUvQCCwTR?= MoPzNVk5QTZ6NEi=
HUVEC cells NWrq[WV2S3m2b4TvfIlkyqCjc4PhfS=> NUHmeZgzPzJiaB?= NXj0OYM3S3m2b4TvfIlkcXS7IHHnZYlve3RiSGXWSWMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOTDuUS=> MUSyOVI4PzB4Nx?=
human HCT116 cells NIrPU2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3u1cGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyxiR1m1NF0zOSCwTR?= M3HzTlE5OjR|N{Cz
K562 cell NWDmXpJFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHv2W4hKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDoeY1idiCuZYXr[Y1q[SCNNU[yJINmdGxibHnu[ZMtKEmFNUC9NlIvOSCwTR?= NYPBVYl4OTV4NUi4O|k>
HT-29 cell Mli2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIOzdJBKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDoeY1idiClb3zvdoVkfGGuIHPhdoNqdm:vYTDIWE0zQSClZXzsJIxqdmW|LDDJR|UxRTJ2LkWgcm0> M3zqT|E2PjV6OEe5
HCT116 cells M1;ScHBzd2yrZnXyZZRqd25iYYPzZZk> MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDifUBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUC9NE4xOyEQvF2= NUnWVXhCOjF4MEW5O|U>
NCI-H1975 cells NFfvVJFRem:uaX\ldoF1cW:wIHHzd4F6 M{DDWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{NCCLQ{WwQVM3KG6P M1jNNVIyPzF3MU[1
human DLD1 cells M4m5e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7hXmtIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFVERzIHPlcIx{NCCJSUWwQVM4KG6P NETIVGMyQDJ2M{ewNy=>
human A431 cells NYfnTJB3S3m2b4TvfIlkyqCjc4PhfS=> M1LPOFczKGh? MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NECgcm0> NHG1fZYzPTJ5N{C2Oy=>
human HepG2 cells MkiyR5l1d3SxeHnjxsBie3OjeR?= NYW5dVdTPzJiaB?= NXXaU5l2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01OCCwTR?= M2DvW|I2Ojd5ME[3
human BGC823 cells MVvDfZRwfG:6aXRCpIF{e2G7 NHXr[Xg4OiCq NHzaWm1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01OCCwTR?= MnHDNlUzPzdyNke=
human SKBR3 cells MVfDfZRwfG:6aXRCpIF{e2G7 NH\YNXk4OiCq NH\Te5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0KUMzDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubITpeIVzNWeubzDhd5NigSxiSVO1NF01OSCwTR?= Mk\aNVk1ODV3Mki=
human MDA-MB-231 cells NUDZfFdUS3m2b4TvfIlkyqCjc4PhfS=> NH\Wb3I4OiCq MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PTBibl2= NGLpNWwzPTJ5N{C2Oy=>
human A549 cells NIe1WZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn6wS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVU1QSClZXzsd{whT0l3ME22OEBvVQ>? MYCxPFI1OzdyMx?=
Sf9 cells MkTxSpVv[3Srb36gZZN{[Xl? NH20T2ZFcXOybHHj[Y1mdnRib3[gS20uSk:GSWDZJIZzd21iaIXtZY4h\nWubDDs[Y5ofGhiSGPQPVAh[WyyaHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmPUBk\WyuczDh[pRmeiBzNjDodpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhUUN3ME23OEBvVQ>? M{\ZRVI1PzVzNESx
human U87MG cells M{Tyd3Bzd2yrZnXyZZRqd25iYYPzZZk> MnHnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEfNS{Bk\WyuczygTWM2OD16OTDuUS=> M{PrOVIyPzF3MU[1
human A549 cells MmHnR5l1d3SxeHnjxsBie3OjeR?= M4HtNlczKGh? M1zkcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25O{BvVQ>? NWfR[Il7OjV{N{ewOlc>
mouse P19 cells M3rrNGN6fG:2b4jpZ:Kh[XO|YYm= NIHWV2cyQCCq NXjx[|ZOS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhWDF7IHPlcIx{KGGodHXyJFE5KGi{czygTWM2OD1yLkGg{txO NYTZcVFVOTd2NEK1OlU>
human HL7702 cells MnHUR5l1d3SxeHnjxsBie3OjeR?= M3vpUlczKGh? NF70VJNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDd5MEKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjF2MTFOwG0> NX\Qem81OjV{N{ewOlc>
human A549 cells M3jJVWN6fG:2b4jpZ:Kh[XO|YYm= M1LKblIh\GG7cx?= M1j2bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgNkBl[Xm|IHL5JGFt[W2jclLseYUh[XO|YYmsJGlEPTB;MD6xOUDPxE1? NYC5ZYdZOjN7NEe3PVQ>
human A431 cells M33xTHBzd2yrZnXyZZRqd25iYYPzZZk> M{\zN|czKGh? MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2M{GgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyPUCuNkDPxE1? MYSyNFY2PTJ|Nx?=
human HepG2 cells M3Tn[2N6fG:2b4jpZ:Kh[XO|YYm= MlzSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTBwMzFOwG0> M4\rcVI{PjV4NUW2
human SW480 cells NHrvNYhEgXSxdH;4bYPDqGG|c3H5 NInXWno4OiCq MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|Q5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|Eh|ryP M1fYbVI2Ojd5ME[3
human LNCAP cells MWHDfZRwfG:6aXRCpIF{e2G7 M{TyelczKGh? MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOFMh|ryP MX:yOVExPTl{NB?=
human LS174T cells MnfjR5l1d3SxeHnjxsBie3OjeR?= Mo\4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHMyPzSWIHPlcIx{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkS1JO69VQ>? MVuxO|A{PDF|NR?=
human HeLa cells MkLDR5l1d3SxeHnjxsBie3OjeR?= M3PM[lczKGh? MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD63PVgh|ryP MkX6NlUzPzdyNke=
rat L6 cells MofnR5l1d3SxeHnjxsBie3OjeR?= NX7sOlVSPzJiaB?= MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBz[XRiTE[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCLQ{WwQVUh|ryP NHjrXIwzPDV6MEWzNS=>
human MCF7 cells MUXDfZRwfG:6aXRCpIF{e2G7 MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiSVO1NF06NjZizszN MUOxPVU3ODN3Mx?=
human MCF7 cells NXq3T3Z1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxRTN3Lk[g{txO M3LQSFE4QDZ7MEm4
HEK293T cells NIfSS|VHfW6ldHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKE6ILXvhdJBiSiCjY4TpeoF1cW:wIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? M{XKcVE5PDB6N{Gz
human Jurkat cells MmLtSpVv[3Srb36gZZN{[Xl? M3vXNGlvcGmkaYTpc44hd2ZiVF7GMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36g[ZhxemW|c3XkJIlvKE[DRFSg[IVncWOrZX70JIh2dWGwIFr1dotifCClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= NVnhS2ZUOTh2MEi3NVM>
human SKBR3 cells NYD2TFJQTnWwY4Tpc44h[XO|YYm= NIDBe4kzPCCq NVvEb4tpUW6qaXLpeIlwdiCxZjDId5A6OC2vZXTpZZRm\CCKRWKyJIRm\3KjZHH0bY9vKGmwIHj1cYFvKFONQmKzJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4S= M3XzUVE5QDF4MUGx

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Geldanamycin (50 mg//kg) shows 30% inhibition on pl85-associated phosphotyrosine levels in FRE/erbB-2 mice. [6]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Isothermal Titration Calorimetry (ITC) of Nucelotide Binding:

The titration experiments are performed using the MSC system. In each experiment, 16 aliquots of 15 μL of geldanamycin (300 μM in 1% DMSO) are injected into 1.3 mL of protein (31 μM in 20 mMTris-HCl, pH 7.5, 1 mMEDTA) at 25 °C, and the resulting data are fit after subtracting the heats of dilution. Heats of dilution are determined in separate experiments from addition of geldanamycin into buffer and buffer into protein. No evidence for binding of DMSO in the nucleotide binding site is observed. Titration data are fit using a nonlinear least-squares curve-fitting algorithm with three floating variables: stoichiometry, binding constant (Kb) 1/Kd), and change of enthalpy of interaction (ΔH°). Dissociation constants estimated for geldanamycin binding to intact yeast Hsp90 is 1.22 μM, and for binding to Hsp90 N-terminal domain is 0.78 μM. No meaningful heat is observed with binding to the C-terminal fragment.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780 human ovarian cell line
  • 濃度: 0.001-10 μM
  • 反応時間: 3 hours
  • 実験の流れ:

    Exponentially growing cells are treated with Geldanamycin and at various times DNA synthesis is assessed by incorporation of bromodeoxyuridine (BrdUrd) and flow cytometric analysis. No marked difference in total cell number is noted during this time course for treated and untreated cultures. BrdUrd (10 μM) is incorporated over a 4-h incubation period at 37 °C and cells are harvested and fixed in 70% ethanol. After denaturation of the DNA with 2 N HC1, cells are incubated with an anti-BrdUrd mouse monoclonal antibody followed by a fluorescein isothiocyanate (FITC)-linked goat anti-mouse IgG. Cells are stained for 30 minutes at room temperature with propidium iodide and analysed by flow cytometry using a Coulter EPICS Profile Analyzer.


    (参考用のみ)
動物試験:

[6]

+ 展開
  • 動物モデル: FRE/erbB-2 tumors in nu/nu mice
  • 製剤: Geldanamycin is dissolved in DMSO.
  • 投薬量: 50 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 36 mg/mL (64.21 mM) warming
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 560.64
化学式

C29H40N2O9

CAS No. 30562-34-6
保管
in solvent
別名 NSC 122750

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HSP (e.g. HSP90)シグナル伝達経路

HSP (e.g. HSP90) Inhibitors with Unique Features

相関HSP (e.g. HSP90)製品

Tags: Geldanamycinを買う | Geldanamycin ic50 | Geldanamycin供給者 | Geldanamycinを購入する | Geldanamycin費用 | Geldanamycin生産者 | オーダーGeldanamycin | Geldanamycin化学構造 | Geldanamycin分子量 | Geldanamycin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID